Prevalence and Characteristics of Covid-19-Associated Pulmonary Diagnoses in Lung Transplant Patients in the United States
1Research Department, United Network for Organ Sharing, Richmond, VA, 2Respiratory Institute, Cleveland Clinic, Cleveland, OH, 3Scientific Registry of Transplant Recipients, Minneapolis, MN, 4Division of Pulmonary, Critical Care, and Sleep Medicine, University of Washington, Seattle, WA
Meeting: 2022 American Transplant Congress
Abstract number: 41
Keywords: COVID-19, Infection, Lung transplantation
Topic: Clinical Science » Lung » 64 - Lung: All Topics
Session Information
Session Name: Infectious Considerations for Lung Transplantation
Session Type: Rapid Fire Oral Abstract
Date: Sunday, June 5, 2022
Session Time: 3:30pm-5:00pm
Presentation Time: 3:30pm-3:40pm
Location: Hynes Room 210
*Purpose: Lung transplant may be a viable treatment option for select patients with non-recoverable COVID-19-associated acute respiratory distress syndrome (ARDS) and COVID-19-associated pulmonary fibrosis. This study aims to characterize the utilization and outcomes of lung transplant among patients with COVID-19-associated ARDS and pulmonary fibrosis.
*Methods: We analyzed the Organ Procurement Transplant Network database to characterize the prevalence and characteristics of patients with COVID-19-associated ARDS and pulmonary fibrosis who were added to the waiting list and/or received a lung transplant between March 13, 2020 and July 31, 2021.
*Results: We found that 207 lung candidate registrations were added to the waiting list and 182 lung transplants were conducted for patients with COVID-19-associated ARDS or pulmonary fibrosis. The majority of lung candidates and lung transplant recipients with COVID-19-associated diagnoses were male, had private insurance, were disproportionately Hispanic and had a higher lung allocation scores (LAS) compared to patients with non-COVID-19 diagnoses. There was no significant difference in 30-day post-transplant survival among recipients with COVID-19-associated diagnoses compared to non-COVID-19 diagnoses.
*Conclusions: Future research on post-transplant outcomes among lung transplant recipients with COVID-19-associated diagnoses is warranted. Further study of outcomes may assist in refining the appropriate LAS waitlist mortality and post-transplant survival scoring for these patients.
To cite this abstract in AMA style:
Mupfudze TG, Wilk AR, Goff RR, Valapour M, Miller J, Budev M, Lease ED. Prevalence and Characteristics of Covid-19-Associated Pulmonary Diagnoses in Lung Transplant Patients in the United States [abstract]. Am J Transplant. 2022; 22 (suppl 3). https://atcmeetingabstracts.com/abstract/prevalence-and-characteristics-of-covid-19-associated-pulmonary-diagnoses-in-lung-transplant-patients-in-the-united-states/. Accessed May 11, 2025.« Back to 2022 American Transplant Congress